Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials
Context Ustekinumab and briakinumab, monoclonal antibodies to the shared p40 subunit of
interleukin (IL)-12 and IL-23, have shown efficacy in treating chronic plaque psoriasis (CPP).
Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patients
receiving anti–IL-12/23 agents have prompted concern. Objective To evaluate a possible
association between biologic therapies for CPP and MACEs via meta-analysis. Data
Sources Randomized controlled trials (RCTs) of anti–IL-12/23 (ustekinumab and …
interleukin (IL)-12 and IL-23, have shown efficacy in treating chronic plaque psoriasis (CPP).
Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patients
receiving anti–IL-12/23 agents have prompted concern. Objective To evaluate a possible
association between biologic therapies for CPP and MACEs via meta-analysis. Data
Sources Randomized controlled trials (RCTs) of anti–IL-12/23 (ustekinumab and …
